Infliximab (Remicade ) to Treat Dermatomyositis and Polymyositis
NCT ID: NCT00033891
Last Updated: 2019-12-03
Study Results
Results pending
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
Recruitment Status
COMPLETED
Clinical Phase
PHASE2
Total Enrollment
14 participants
Study Classification
INTERVENTIONAL
Study Start Date
2002-04-10
Study Completion Date
2010-05-20
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
This study will examine whether infliximab (Remicade ) is safe and effective for the treatment of dermatomyositis and polymyositis. Infliximab blocks the effect of a protein called tumor necrosis factor (TNF), which is associated with harmful inflammation in many diseases.
Patients 18 years of age and older with active dermatomyositis or polymyositis that does not respond adequately to treatment with methotrexate and corticosteroids may be eligible for this study. Candidates will be screened with a medical history, physical examination, blood and urine tests, chest x-ray, pulmonary function test, skin test for tuberculosis, HIV test, electromyography (described below), manual muscle testing, and functional assessments. Magnetic resonance imaging (described below) will be done to assess the degree and location of inflammation in the involved limbs. An electrocardiogram and echocardiogram will be done if recent ones are not available. Patients who qualify for the study will be asked to undergo two muscle biopsies (surgical removal and analysis of small pieces of muscle tissue), one before initiation of treatment and another on the 16th week .
Participants will be randomly assigned to receive either 3 mg/kg body weight of infliximab or a placebo (inactive substance) by infusion through a vein over 2 hours. The infusions will be given at the beginning of the treatment period (week 0) and at weeks 2, 6 and 14. At week 16, strength will be assessed by manual muscle testing. Patients who improved with treatment will continue with the same infusion dose on weeks 18, 22, 30, and 38. Those who do not improve will be assigned by random allocation to receive either 5 mg/kg body weight or 10/mg/kg body weight of infliximab on weeks 18, 22, 30 and 38. Those who did not improve who were previously on the placebo infusion will receive an extra dose of either 5 mg/kg or 10 mg/kg body weight of infliximab on week 16, while those patients who were previously on 3 mg/kg body weight of infliximab who failed to meet the improvement criteria will receive an infusion containing no medication on week 16. Patients will be admitted to the hospital for infusions at weeks 0, 14 and 38; the rest will be given on an outpatient basis. After the 38th week, all infusions will be stopped and patients will be assessed on the 40th week.
Participants will undergo some or all of the following tests and evaluations during treatment:
* Blood tests every week to look for antibodies seen with muscle inflammation. Some of the blood samples will be stored for later testing, including genetic studies to find genetic differences related to inflammation.
* Skin test for tuberculosis
* Chest x-rays at the beginning of the study (if a recent one is not available) and again at weeks 16 and 40 to look for active infection, detect signs of past exposure or infection with diseases such as tuberculosis, and assess the presence of lung disease that might be related to the myositis.
* MRI (usually of the legs) at the beginning of the study and again at weeks 16 and 40 to measure disease activity and extent of muscle involvement. This will also give an idea of the response to treatment. This test uses a magnetic field and radio waves to produce images of body tissues. During the procedure the patient lies on a bed surrounded by a metal cylinder (the scanner).
* Muscle biopsy at the beginning of the study to diagnose muscle inflammation and again at week 16 to evaluate the response to treatment.
* Electromyography if the patient has not had an EMG previously. For this test, small needles are inserted into the muscle to assess the electrical activity of the muscle
* HIV test
Patients whose disease worsen with treatment or who develop serious drug-related side effects will be taken off the study and referred back to their primary care physician for further therapy. Patients who improve will be referred back to their primary physician at the end of the study for possible continued treatment. Participants will be asked to return for follow-up visits every 6 weeks for a total of 30 weeks to monitor long-term effects of the drug
Patients 18 years of age and older with active dermatomyositis or polymyositis that does not respond adequately to treatment with methotrexate and corticosteroids may be eligible for this study. Candidates will be screened with a medical history, physical examination, blood and urine tests, chest x-ray, pulmonary function test, skin test for tuberculosis, HIV test, electromyography (described below), manual muscle testing, and functional assessments. Magnetic resonance imaging (described below) will be done to assess the degree and location of inflammation in the involved limbs. An electrocardiogram and echocardiogram will be done if recent ones are not available. Patients who qualify for the study will be asked to undergo two muscle biopsies (surgical removal and analysis of small pieces of muscle tissue), one before initiation of treatment and another on the 16th week .
Participants will be randomly assigned to receive either 3 mg/kg body weight of infliximab or a placebo (inactive substance) by infusion through a vein over 2 hours. The infusions will be given at the beginning of the treatment period (week 0) and at weeks 2, 6 and 14. At week 16, strength will be assessed by manual muscle testing. Patients who improved with treatment will continue with the same infusion dose on weeks 18, 22, 30, and 38. Those who do not improve will be assigned by random allocation to receive either 5 mg/kg body weight or 10/mg/kg body weight of infliximab on weeks 18, 22, 30 and 38. Those who did not improve who were previously on the placebo infusion will receive an extra dose of either 5 mg/kg or 10 mg/kg body weight of infliximab on week 16, while those patients who were previously on 3 mg/kg body weight of infliximab who failed to meet the improvement criteria will receive an infusion containing no medication on week 16. Patients will be admitted to the hospital for infusions at weeks 0, 14 and 38; the rest will be given on an outpatient basis. After the 38th week, all infusions will be stopped and patients will be assessed on the 40th week.
Participants will undergo some or all of the following tests and evaluations during treatment:
* Blood tests every week to look for antibodies seen with muscle inflammation. Some of the blood samples will be stored for later testing, including genetic studies to find genetic differences related to inflammation.
* Skin test for tuberculosis
* Chest x-rays at the beginning of the study (if a recent one is not available) and again at weeks 16 and 40 to look for active infection, detect signs of past exposure or infection with diseases such as tuberculosis, and assess the presence of lung disease that might be related to the myositis.
* MRI (usually of the legs) at the beginning of the study and again at weeks 16 and 40 to measure disease activity and extent of muscle involvement. This will also give an idea of the response to treatment. This test uses a magnetic field and radio waves to produce images of body tissues. During the procedure the patient lies on a bed surrounded by a metal cylinder (the scanner).
* Muscle biopsy at the beginning of the study to diagnose muscle inflammation and again at week 16 to evaluate the response to treatment.
* Electromyography if the patient has not had an EMG previously. For this test, small needles are inserted into the muscle to assess the electrical activity of the muscle
* HIV test
Patients whose disease worsen with treatment or who develop serious drug-related side effects will be taken off the study and referred back to their primary care physician for further therapy. Patients who improve will be referred back to their primary physician at the end of the study for possible continued treatment. Participants will be asked to return for follow-up visits every 6 weeks for a total of 30 weeks to monitor long-term effects of the drug
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
A Study of Infliximab in Patients With Sarcoidosis
NCT00073437
Sarcoidosis
COMPLETED
PHASE3
Efficacy and Tolerability of BAF312 in Patients With Polymyositis and Dermatomyositis
NCT01148810
Polymyositis
Dermatomyositis
TERMINATED
PHASE2
Use of Infliximab for the Treatment of Pemphigus Vulgaris
NCT00283712
Pemphigus
COMPLETED
PHASE2
Study of IFN-K in Dermatomyositis
NCT02980198
Dermatomyositis
WITHDRAWN
PHASE2
A Phase 2 Trial of Infliximab in Coronavirus Disease 2019 (COVID-19).
NCT04425538
COVID-19
COMPLETED
PHASE2
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Tumor necrosis factor (TNF), a cytokine that has been implicated in the pathogenesis of many diseases including inflammatory disorders, has been found to be elevated in the muscles of patients with dermatomyositis (DM) and polymyositis (PM). A subset of patients with DM and PM do not respond readily to conventional therapy. Therefore, a controlled trial using infliximab, a chimeric IgG(1) kappa monoclonal antibody against TNF, may provide a therapeutic option and advance understanding in the pathogenesis of these diseases. This study is designed to determine the safety and efficacy of infliximab in patients with DM and PM. We plan to enroll a maximum of 28 patients randomized at 1:1 ratio into 2 groups, placebo vs. infliximab at 5 mg/kg body weight. In the first phase of the study the placebo and infliximab infusions will be given at week 0, 2, 6 and 14. Primary outcome assessment will be done at week 16. Those who respond according to the criteria set for improvement in MMT will be given the option to remain on the same infusion (i.e. placebo or infliximab at 5 mg/kg body weight) at weeks 22, 30 and 38. Placebo non-responders will be given infliximab at 5 mg/kg body weight in an open label fashion at weeks 16, 18, 22, 30 and 38. Patients who were initially on 5 mg/kg body weight of infliximab who failed to respond based on the criteria set will be placed on infliximab at 7.5 mg/kg body weight in an open label fashion on weeks 22, 30 and 38. Pharmacokinetic modeling will be done in both phases of the study. A muscle biopsy will be done before treatment and again at 16 weeks of treatment. Microarray gene expression profiling of the muscle biopsy specimens will be done before treatment and again at 16 weeks. Clinical, functional and serological evaluations will be performed in every visit to assess other responses to treatment. Patients will be followed for 30 weeks after study termination to evaluate the long-term effects of the drug.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Dermatomyositis
Polymyositis
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
Allocation Method
RANDOMIZED
Intervention Model
CROSSOVER
Primary Study Purpose
TREATMENT
Blinding Strategy
QUADRUPLE
Participants
Caregivers
Investigators
Outcome Assessors
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Infliximab
Intervention Type
DRUG
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Must be at least 18 years of age.
Diagnosis of probable or definite polymyositis or dermatomyositis as defined by Bohan and Peter:
i. Symmetrical proximal muscle weakness;
ii. Muscle biopsy abnormalities at some time during their disease:
1. Muscle fiber destruction;
2. Muscle fiber regeneration;
3. Perivascular and interstitial inflammatory infiltrates with muscle fiber destruction.
iii. Elevation of serum creatine phosphokinase (CPK), Transaminases, lactic dehydrogenase (LDH) or aldolase activity;
iv. Electromyography changes:
1. Fibrillation potentials (on needle insertion at rest);
2. Complex repetitive discharges (on needle insertion at rest);
3. Positive sharp waves (on needle insertion at rest);
4. Short duration, low amplitude complex (polyphasic) potentials on contraction.
v. Typical skin rash. The classic skin manifestations include a purplish discoloration of the eyelids (heliotrope rash) or papular, erythematous, scaly lesions over the knuckles (Gottron s papules);
DEFINITE: any 4 of the criteria
PROBABLE: any 3 of the criteria
* Patients must have a baseline total muscle strength score of less than or equal to 120 but not less than 80 on manual muscle testing (MMT) or at least 25% decrease in manual muscle strength.
* Ability to provide informed consent to all aspects of the study after full information is provided.
* Evidence of active disease as measured by weakness, and an elevated CK, aldolase, SGOT, SGPT, LDH or an active MRI. MR imaging may demonstrate signal abnormalities in affected muscles secondary to inflammation and edema on STIR images.
* Patients must be on a stable dose of prednisone equal to or less than 0.5 mg/kg/day for 1 month prior to the study.
* Patients must be on at least 7.5 mg of methotrexate weekly or at least 75 mg of azathioprine daily for at least 4 weeks prior to the study.
* Patients must not be on any other cytotoxic agents for at least 1 month prior to the study.
* Women of childbearing potential and men whose partners are of childbearing potential must practice an acceptable form of contraception.
* No prior history of treatment with monoclonal antibodies, i.e. no prior history of infliximab therapy.
* Patients with active disease despite previous treatment with at least one other immunosuppressive agent and/or intolerable side effects: e.g. high-dose prednisone (1 mg/kg/day), methotrexate 12.5 to 20 mg/wk, azathioprine 100-150 mg/day, cyclosporineA 2-2.5 mg/kg/day and cyclophosphamide 1-2 mg/kg/day.
Diagnosis of probable or definite polymyositis or dermatomyositis as defined by Bohan and Peter:
i. Symmetrical proximal muscle weakness;
ii. Muscle biopsy abnormalities at some time during their disease:
1. Muscle fiber destruction;
2. Muscle fiber regeneration;
3. Perivascular and interstitial inflammatory infiltrates with muscle fiber destruction.
iii. Elevation of serum creatine phosphokinase (CPK), Transaminases, lactic dehydrogenase (LDH) or aldolase activity;
iv. Electromyography changes:
1. Fibrillation potentials (on needle insertion at rest);
2. Complex repetitive discharges (on needle insertion at rest);
3. Positive sharp waves (on needle insertion at rest);
4. Short duration, low amplitude complex (polyphasic) potentials on contraction.
v. Typical skin rash. The classic skin manifestations include a purplish discoloration of the eyelids (heliotrope rash) or papular, erythematous, scaly lesions over the knuckles (Gottron s papules);
DEFINITE: any 4 of the criteria
PROBABLE: any 3 of the criteria
* Patients must have a baseline total muscle strength score of less than or equal to 120 but not less than 80 on manual muscle testing (MMT) or at least 25% decrease in manual muscle strength.
* Ability to provide informed consent to all aspects of the study after full information is provided.
* Evidence of active disease as measured by weakness, and an elevated CK, aldolase, SGOT, SGPT, LDH or an active MRI. MR imaging may demonstrate signal abnormalities in affected muscles secondary to inflammation and edema on STIR images.
* Patients must be on a stable dose of prednisone equal to or less than 0.5 mg/kg/day for 1 month prior to the study.
* Patients must be on at least 7.5 mg of methotrexate weekly or at least 75 mg of azathioprine daily for at least 4 weeks prior to the study.
* Patients must not be on any other cytotoxic agents for at least 1 month prior to the study.
* Women of childbearing potential and men whose partners are of childbearing potential must practice an acceptable form of contraception.
* No prior history of treatment with monoclonal antibodies, i.e. no prior history of infliximab therapy.
* Patients with active disease despite previous treatment with at least one other immunosuppressive agent and/or intolerable side effects: e.g. high-dose prednisone (1 mg/kg/day), methotrexate 12.5 to 20 mg/wk, azathioprine 100-150 mg/day, cyclosporineA 2-2.5 mg/kg/day and cyclophosphamide 1-2 mg/kg/day.
Exclusion Criteria
Patients with inclusion body myositis or cancer-related or drug-induced myopathy.
History of hepatitis or abnormal liver function tests which do not reflect muscle disease.
History of recurrent infections, any active acute or chronic infections requiring antimicrobial therapy, or serious viral (e.g. Hepatitis B positivity, herpes zoster, herpes simplex, HIV positivity, hepatitis C or A, CMV) or fungal infections such as histoplasmosis, aspergillosis, coccidiodomycosis. Patients with positive PPD who have cavitary lesions suspicious for active tuberculosis will be excluded. In addition, patients with a positive PPD who decline INH prophylaxis will be excluded. Any patients with suspected pneumonia, cellulitis, pneumocystis carini, and infection at central venous catheter site will also be excluded.
Patients with suspicious lesions on chest radiography suggestive of an infectious or neoplastic condition will be excluded.
Pregnant females, nursing mothers, or patients of childbearing age not practicing birth control.
Preexisting or coexisting malignancy other than basal cell carcinoma and localized squamous cell carcinoma of the skin.
Patients who have not had any recent age-appropriate malignancy screen within the past 3 months who refuse to have said age-appropriate malignancy screening procedures prior to the start of the study.
History of cerebrovascular accidents, seizure disorder, aseptic meningitis, transverse myelitis, central nervous system demyelinating disease such as multiple sclerosis.
Confounding medical illness that in the judgment of the investigators pose added risk for study participants (e.g. chronic lung or hematological disease).
Anemia requiring maintenance blood transfusions; leukopenia with WBC less than 3,000/ul or absolute neutrophil count less than 2,000/ul; platelet count less than 100,000/ul on at least two different occasions.
History of (or current) autoimmune hemolytic anemia.
Current anticoagulant therapy.
History of lupus erythematosus (+)ANA: dsDNA, anti-Smith, anti-Ro/La and clinical presentation consistent with lupus erythematosus.
Clotting/bleeding disorders history of arterial or venous thrombosis, stroke, miscarriages and presence of antiphospholipid antibodies, protein C or protein S deficiency along with a compatible history of a thrombotic event.
History of psychiatric illness that in the opinion of psychiatric consultants would pose an added risk for study participants.
History of uncontrolled diabetes mellitus.
Prior use of infliximab.
Current use of a TNF-blocking agent (patient has to be off for 4 weeks). Prior use of etanercept is accepted so long as patient has been off of it for 4 weeks.
Allergy to murine-derived products.
Poor venous access.
History of live vaccinations within the past 3 months.
History of drug abuse within the past 5 years.
History of congestive heart failure.
Echocardiographic evidence of dilated or hypertrophic cardiomyopathy.
Echocardiographic evidence of valvular stenosis or regurgitation that in the judgment of the physician poses a risk for congestive heart failure.
History of significant arrhythmia requiring pacing or cardioversion.
EKG or echocardiographic evidence of ventricular hypertrophy and clinical signs of congestive heart failure.
History of hepatitis or abnormal liver function tests which do not reflect muscle disease.
History of recurrent infections, any active acute or chronic infections requiring antimicrobial therapy, or serious viral (e.g. Hepatitis B positivity, herpes zoster, herpes simplex, HIV positivity, hepatitis C or A, CMV) or fungal infections such as histoplasmosis, aspergillosis, coccidiodomycosis. Patients with positive PPD who have cavitary lesions suspicious for active tuberculosis will be excluded. In addition, patients with a positive PPD who decline INH prophylaxis will be excluded. Any patients with suspected pneumonia, cellulitis, pneumocystis carini, and infection at central venous catheter site will also be excluded.
Patients with suspicious lesions on chest radiography suggestive of an infectious or neoplastic condition will be excluded.
Pregnant females, nursing mothers, or patients of childbearing age not practicing birth control.
Preexisting or coexisting malignancy other than basal cell carcinoma and localized squamous cell carcinoma of the skin.
Patients who have not had any recent age-appropriate malignancy screen within the past 3 months who refuse to have said age-appropriate malignancy screening procedures prior to the start of the study.
History of cerebrovascular accidents, seizure disorder, aseptic meningitis, transverse myelitis, central nervous system demyelinating disease such as multiple sclerosis.
Confounding medical illness that in the judgment of the investigators pose added risk for study participants (e.g. chronic lung or hematological disease).
Anemia requiring maintenance blood transfusions; leukopenia with WBC less than 3,000/ul or absolute neutrophil count less than 2,000/ul; platelet count less than 100,000/ul on at least two different occasions.
History of (or current) autoimmune hemolytic anemia.
Current anticoagulant therapy.
History of lupus erythematosus (+)ANA: dsDNA, anti-Smith, anti-Ro/La and clinical presentation consistent with lupus erythematosus.
Clotting/bleeding disorders history of arterial or venous thrombosis, stroke, miscarriages and presence of antiphospholipid antibodies, protein C or protein S deficiency along with a compatible history of a thrombotic event.
History of psychiatric illness that in the opinion of psychiatric consultants would pose an added risk for study participants.
History of uncontrolled diabetes mellitus.
Prior use of infliximab.
Current use of a TNF-blocking agent (patient has to be off for 4 weeks). Prior use of etanercept is accepted so long as patient has been off of it for 4 weeks.
Allergy to murine-derived products.
Poor venous access.
History of live vaccinations within the past 3 months.
History of drug abuse within the past 5 years.
History of congestive heart failure.
Echocardiographic evidence of dilated or hypertrophic cardiomyopathy.
Echocardiographic evidence of valvular stenosis or regurgitation that in the judgment of the physician poses a risk for congestive heart failure.
History of significant arrhythmia requiring pacing or cardioversion.
EKG or echocardiographic evidence of ventricular hypertrophy and clinical signs of congestive heart failure.
Minimum Eligible Age
18 Years
Eligible Sex
ALL
Accepts Healthy Volunteers
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
NIH
Sponsor Role
lead
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Responsibility Role
SPONSOR
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Adam I Schiffenbauer, M.D.
Role: PRINCIPAL_INVESTIGATOR
National Institute of Environmental Health Sciences (NIEHS)
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
National Institutes of Health Clinical Center, 9000 Rockville Pike
Bethesda, Maryland, United States
Site Status
Countries
Review the countries where the study has at least one active or historical site.
United States
References
Explore related publications, articles, or registry entries linked to this study.
Joffe MM, Love LA, Leff RL, Fraser DD, Targoff IN, Hicks JE, Plotz PH, Miller FW. Drug therapy of the idiopathic inflammatory myopathies: predictors of response to prednisone, azathioprine, and methotrexate and a comparison of their efficacy. Am J Med. 1993 Apr;94(4):379-87. doi: 10.1016/0002-9343(93)90148-i.
Reference Type
BACKGROUND
Love LA, Leff RL, Fraser DD, Targoff IN, Dalakas M, Plotz PH, Miller FW. A new approach to the classification of idiopathic inflammatory myopathy: myositis-specific autoantibodies define useful homogeneous patient groups. Medicine (Baltimore). 1991 Nov;70(6):360-74. doi: 10.1097/00005792-199111000-00002.
Reference Type
BACKGROUND
Oddis CV, Conte CG, Steen VD, Medsger TA Jr. Incidence of polymyositis-dermatomyositis: a 20-year study of hospital diagnosed cases in Allegheny County, PA 1963-1982. J Rheumatol. 1990 Oct;17(10):1329-34.
Reference Type
BACKGROUND
Schiffenbauer A, Garg M, Castro C, Pokrovnichka A, Joe G, Shrader J, Cabalar IV, Faghihi-Kashani S, Harris-Love MO, Plotz PH, Miller FW, Gourley M. A randomized, double-blind, placebo-controlled trial of infliximab in refractory polymyositis and dermatomyositis. Semin Arthritis Rheum. 2018 Jun;47(6):858-864. doi: 10.1016/j.semarthrit.2017.10.010. Epub 2017 Oct 16.
Reference Type
DERIVED
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
02-AR-0156
Identifier Type: -
Identifier Source: secondary_id
020156
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.
Safety and Efficacy of BAF312 in Dermatomyositis
NCT02029274
TERMINATED
PHASE2
Safety and Effectiveness of h5G1.1-mAb for Dermatomyositis
NCT00005571
COMPLETED
PHASE2
Infliximab to Treat Children With Juvenile Rheumatoid Arthritis
NCT00029042
TERMINATED
PHASE2
A Study of Safety and Efficacy of Infliximab (Remicade) in Patients With COPD
NCT00056264
COMPLETED
PHASE3
A Long-term Safety Study of Infliximab (Remicade)
NCT00261976
COMPLETED
Study of Deucravacitinib for Refractory Adults With Dermatomyositis/Juvenile Dermatomyositis
NCT07012057
WITHDRAWN
PHASE2
Belimumab With Rituximab for Primary Membranous Nephropathy
NCT03949855
RECRUITING
PHASE2
A Study of the Safety and Effectiveness of Infliximab (Remicade) in Patients With Giant Cell Arteritis
NCT00076726
TERMINATED
PHASE2
A Study to Investigate Mepolizumab in the Treatment of Eosinophilic Granulomatosis With Polyangiitis
NCT02020889
COMPLETED
PHASE3
Study to Assess the Safety and Efficacy of Infliximab to Treat Hidradenitis Suppurtativa
NCT00795574
COMPLETED
PHASE2
Safety, Tolerability, and Efficacy of JBT-101 in Subjects With Dermatomyositis
NCT02466243
TERMINATED
PHASE2
Evaluating Safety & Efficacy of Apremilast in the Treatment of Cutaneous Disease in Patients With Recalcitrant Dermatomyositis
NCT03529955
COMPLETED
PHASE2
Multi Center Prospective Registry of Infliximab Use for Childhood Uveitis
NCT00589628
COMPLETED
PHASE4
To Assess the Safety, Tolerability and Efficacy of Itacitinib Immediate Release Tablets in Participants With Primary or Secondary Myelofibrosis Who Have Received Prior Ruxolitinib and/or Fedratinib Monotherapy (LIMBER-213)
NCT04629508
COMPLETED
PHASE2
Ixekizumab in the Treatment of Bullous Pemphigoid
NCT03099538
COMPLETED
PHASE2
Depemokimab in Participants With Hypereosinophilic Syndrome, Efficacy, and Safety Trial
NCT05334368
RECRUITING
PHASE3
Efficacy and Safety Study of Mepolizumab in Subjects With Moderate to Severe Atopic Dermatitis
NCT03055195
TERMINATED
PHASE2
A Study of Ustekinumab in Participants With Active Polymyositis and Dermatomyositis Who Have Not Adequately Responded to One or More Standard-of-care Treatments
NCT03981744
TERMINATED
PHASE3
Infusion Related Reactions in Patients Receiving Infliximab
NCT02332460
UNKNOWN
A Study to Evaluate the Safety and Efficacy of Apremilast in the Treatment of Skin Disease in Patients With Dermatomyositis
NCT01140503
TERMINATED
NA
Randomized Clinical Trial Comparing the Safety and Efficacy of Rituximab Versus Oral Cyclophosphamide in Severe Forms of Mucous Membrane Pemphigoid
NCT03295383
UNKNOWN
PHASE3
Ruxolitinib in Previously Treated Idiopathic Multicentric Castleman Disease
NCT07085039
RECRUITING
PHASE2
A Study to Investigate the Safety and Efficacy of Emapalumab, an Anti-IFN-gamma mAb in Patients With Systemic Juvenile Idiopathic Arthritis (sJIA) or Adult-onset Still's Disease (AOSD) Developing Macrophage Activation Syndrome/Secondary HLH (MAS/sHLH)
NCT03311854
COMPLETED
PHASE2
Beryllium Infliximab Study: Clinical Interventional Trial
NCT00111917
TERMINATED
PHASE1/PHASE2